Start: June 1, 2018
End: December 2025
Tau is a protein that accumulates abnormally in the brains of people with Alzheimer's disease and other dementias. This study will use the new radioactive tracer 18F-MK-6240 in positron emission tomography (PET) scanning to detect tau pathology in older adults who are cognitively healthy and mildly cognitively impaired. Researchers will examine the interactions between tau levels and performance on cognitive tasks, neural activation patterns using functional MRI brain scans, and other cognitive and behavioral measures. The study also aims to examine how the presence of tau may contribute to the risk of subsequent cognitive decline, neurodegeneration, and dementia.
Minimum Age: 55 Years
Maximum Age: 90 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Columbia University Medical Center
New York, NY 10032
RecruitingAshley Mensing, BS
Lead: Yaakov Stern
Source: ClinicalTrials.gov ID: NCT03372317